AEMD:NSD-Aethlon Medical, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.98

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.85M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. The company is based in San Diego, California.

Company Website : http://www.aethlonmedical.com

Address : 9635 Granite Ridge Drive, San Diego, CA, United States, 92123

Employees : 8

Fiscal Year End : March

Currency: USD

Country : USA

Technical Indicators

Beta : 0.73

52 Week High : 6.89

Short Ratio : 0.52

52 Week Low : 0.20

Shorted Shares : 715,684

200 Day Moving Average : 1.82

Shorted Shares Previous Month : 283,833

50 Day Moving Average : 1.73

Shares Held By Insiders : 50.33%

Short Percentage : 3.00%

Shares Held by Institutions : 12.52%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-11 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

N/A

 USD21.53B 11.74 38.90
PODD Insulet Corporation

N/A

 USD13.60B 2,307.67 180.57
ABMD Abiomed, Inc

N/A

 USD11.91B 59.96 42.73
LVGO Livongo Health, Inc

N/A

 USD10.52B N/A N/A
TNDM Tandem Diabetes Care, Inc

N/A

 USD6.18B N/A N/A
BRKR Bruker Corporation

N/A

 USD6.11B 36.51 19.28
IART Integra LifeSciences Holdings ..

N/A

 USD3.94B 157.16 25.21
WMGI Wright Medical Group N.V

N/A

 USD3.85B N/A 41.52
SDC SmileDirectClub, Inc

N/A

 USD3.11B N/A N/A
RCEL AVITA Therapeutics, Inc

N/A

 USD2.91B -99,999.99 N/A

ETFs Containing AEMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 106.25% 91% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.25% 91% A- 93% A
Trailing 12 Months  
Capital Gain 500.00% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 500.00% 97% A+ 98% A+
Trailing 5 Years  
Capital Gain -75.62% 30% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.62% 30% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain -6.13% 10% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.13% 10% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 103.31% 43% F 16% F
Risk Adjusted Return -5.94% 16% F 13% F
Market Capitalization 0.02B 16% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.47 70% C- 45% F
Price / Cash Flow Ratio -4.59 56% F 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -110.22% 38% F 12% F
Return on Invested Capital -92.68% 25% F 10% F
Return on Assets -51.08% 21% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.52 79% C+ 81% B-
Short Percent 3.04% 70% C- 52% F
Beta 0.73 68% D+ 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector